Research map: ERBB2 copy number alterations and protein expression in bladder cancer treated by cystectomy

Back to the article

Papers in this map

  1. Assessment of a HER2 scoring system for gastric cancer: results from a validation study · Manfred Hofmann · 2008 · 1203 citations · Cited by this paper
  2. Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors · 2026 · Related
  3. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  4. Single-section assessment of DNA mismatch repair using PMS2/MSH6 double immunohistochemistry · 2026 · Related
  5. Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/ neu –Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial · Maha Hussain · 2007 · 378 citations · Cited by this paper
  6. Metastatic pancreatic acinar cell carcinoma to the liver mimicking neuroendocrine tumor (NET) and pancreatic ductal adenocarcinoma (PDAC): A series of seven cases · 2026 · Related
  7. A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma · Christian Wülfing · 2009 · 218 citations · Cited by this paper
  8. Morphology spectrum and molecular landscape in eosinophilic solid and cystic renal cell carcinoma · 2026 · Related
  9. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer · Thomas B. Powles · 2017 · 208 citations · Cited by this paper
  10. Histologic spectrum of BRCA-associated pancreatic ductal adenocarcinoma: A descriptive morphologic study · 2026 · Related
  11. Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours · Achim Fleischmann · 2011 · 186 citations · Cited by this paper
  12. GPNMB immunohistochemistry distinguishes diagnostically challenging cases of lymphangioleiomyomatosis from other mesenchymal neoplasms presenting with cystic lung metastases · 2026 · Related
  13. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials · Xinan Sheng · 2023 · 180 citations · Cited by this paper
  14. TSC gene-associated lesions of the lung · 2026 · Related
  15. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2 · Stéphane Marie. Oudard · 2014 · 149 citations · Cited by this paper
  16. Mixed phenotype acute leukemia: Lineage assignment, immunophenotypic classification and genetic insights · 2026 · Related
  17. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization · Christina Barbara Ching · 2011 · 108 citations · Cited by this paper
  18. Molecular Subtypes and Genetic Diagnostics in B-cell Acute Lymphoblastic Leukemia · 2026 · Related
  19. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer · Xinan Sheng · 2025 · 95 citations · Cited by this paper
  20. Clinicopathologic and molecular characteristics of acral melanomas harboring RARA fusions · 2026 · Related
  21. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives · Giorgio Patelli · 2022 · 94 citations · Cited by this paper
  22. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome · Steven A Schneider · 2013 · 83 citations · Cited by this paper
  23. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study · Li Qun Zhou · 2024 · 63 citations · Cited by this paper
  24. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma · Sumit Isharwal · 2018 · 51 citations · Cited by this paper
  25. Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management · Gabriel Dernbach · 2025 · 34 citations · Cited by this paper
  26. Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma. · Xinan Sheng · 2022 · 28 citations · Cited by this paper
  27. Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study · Xieqiao Yan · 2025 · 18 citations · Cited by this paper
  28. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2 · Jessica M. Posada · 2024 · 16 citations · Cited by this paper
  29. Plasmacytoid urothelial carcinoma of the urinary bladder–A clinicopathological and molecular analysis of 52 cases · Lan Zheng · 2024 · 9 citations · Cited by this paper
  30. Untitled · Cited by this paper

Source: OpenAlex (CC0)